HZNP and HPR Related Headlines

Go Back

Aug 4, 2021 07:00AM Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
Jul 16, 2021 08:30AM Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™
Jul 8, 2021 08:00AM Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021
Jul 1, 2021 11:43AM NIRI Chicago Elects 2021-2022 Officers and Directors
Jun 30, 2021 08:00AM Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021
Jun 29, 2021 08:02AM Horizon Therapeutics (HZNP) Enrolls First Patient in Phase 2 Trial of HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Jun 29, 2021 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Jun 28, 2021 09:00AM Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Jun 21, 2021 07:32AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 18, 2021 12:32PM Horizon Therapeutics (HZNP) Announces Multiple Presentations on NMOSD at EAN
Jun 18, 2021 12:30PM Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)
Jun 17, 2021 07:06AM Horizon Therapeutics (HZNP) Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 17, 2021 07:00AM Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 2, 2021 08:00AM Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology
May 27, 2021 08:00AM Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
May 24, 2021 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
May 21, 2021 08:00AM Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology
May 20, 2021 08:30AM Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work®
May 13, 2021 11:30AM Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company
May 6, 2021 04:30PM Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference
May 6, 2021 08:34AM Horizon Therapeutics (HZNP) Announces New Analysis of UPLIZNA for Neuromyelitis Optica Spectrum Disorder Published in Neurology Neuroimmunology & Neuroinflammation
May 6, 2021 08:30AM New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
May 6, 2021 08:00AM Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen’s Association 2021 Luminary
May 5, 2021 07:00AM Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc
Apr 27, 2021 08:00AM Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide
Apr 21, 2021 07:30AM HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout
Apr 20, 2021 04:04AM Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
Apr 16, 2021 08:30AM New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 16, 2021 08:03AM Horizon Therapeutics (HZNP) Announces New Integrated Data and Follow-up Outcomes From Two TEPEZZA Pivotal Trials Published in The Lancet Diabetes & Endocrinology
Apr 16, 2021 08:00AM New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
Apr 12, 2021 08:30AM Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
Apr 8, 2021 08:00AM Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
Apr 7, 2021 08:03AM Horizon Therapeutics (HZNP) RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA with Immunomodulator Mycophenolate Mofetil
Apr 7, 2021 08:00AM RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil
Apr 5, 2021 08:36AM Horizon Therapeutics (HZNP) Announces New UPLIZNA Data in People With Neuromyelitis Optica Spectrum Disorder to be Presented at AAN's 73rd Annual Meeting
Apr 5, 2021 08:30AM New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology’s 73rd Annual Meeting
Mar 30, 2021 07:34AM Horizon Therapeutics (HZNP) to Resupply Market With TEPEZZA for the Treatment of Thyroid Eye Disease Beginning in April
Mar 30, 2021 07:30AM Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April
Mar 29, 2021 10:05AM Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership
Mar 25, 2021 08:00AM First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout
Mar 24, 2021 08:16AM Horizon Therapeutics (HZNP) Announces UPLIZNA Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder
Mar 24, 2021 08:15AM UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mar 24, 2021 08:00AM Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community
Mar 15, 2021 08:50AM Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.
Mar 12, 2021 08:45AM Horizon Therapeutics plc Named Number One Best Workplace in Biopharma
Mar 11, 2021 03:00AM Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
Feb 26, 2021 04:05PM Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference
Feb 25, 2021 04:05PM Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish®
Feb 24, 2021 07:00AM Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance
Feb 22, 2021 09:30AM New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase
Feb 4, 2021 01:00AM Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
Feb 3, 2021 08:00AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021
Feb 1, 2021 07:00AM Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
Jan 11, 2021 07:04AM Horizon Therapeutics (HZNP) Provides Preliminary 2020 Financial Results
Jan 11, 2021 07:00AM Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New K
Dec 22, 2020 08:00AM Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 17, 2020 06:40AM Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production
Dec 3, 2020 09:00AM Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education
Dec 2, 2020 09:15AM Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
Nov 30, 2020 08:00AM Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities
Nov 25, 2020 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 23, 2020 08:05AM Horizon Therapeutics (HZNP) and Halozyme Therapeutics (HALO) Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 23, 2020 08:00AM Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 23, 2020 08:00AM Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 17, 2020 09:15AM National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation
Nov 16, 2020 08:00AM First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease
Nov 13, 2020 08:34AM Horizon Therapeutics (HZNP) Reports New TEPEZZA (teprotumumab-trbw) Data Presented at AAO 2020 Virtual
Nov 13, 2020 08:30AM New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration
Nov 13, 2020 08:00AM Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala
Nov 12, 2020 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 2, 2020 02:00PM Horizon Therapeutics (HZNP) Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Nov 2, 2020 02:00PM Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Nov 2, 2020 07:00AM Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITD
Nov 2, 2020 06:58AM Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
Oct 30, 2020 09:15AM Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
Oct 30, 2020 08:00AM New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting
Oct 29, 2020 03:00PM AGC Biologics and Horizon Therapeutics plc Expand Partnership
Oct 29, 2020 08:00AM Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
Oct 26, 2020 08:00AM Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
Oct 23, 2020 08:00AM Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Oct 22, 2020 10:00AM New Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout
Oct 20, 2020 08:00AM Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award
Oct 16, 2020 08:30AM FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year
Oct 14, 2020 08:03AM Horizon Therapeutics (HZNP) Reports TEPEZZA (teprotumumab-trbw) Data from Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease
Oct 14, 2020 08:00AM TEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)
Oct 8, 2020 08:15AM New Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020
Oct 8, 2020 08:00AM Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020
Oct 7, 2020 08:00AM Horizon Therapeutics plc Named One of San Francisco Bay Area’s Best and Brightest Companies to Work For
Oct 5, 2020 08:00AM Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award
Oct 1, 2020 04:00PM Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption
Sep 16, 2020 08:09AM Horizon Therapeutics (HZNP) MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79% of Patients Achieved Complete Response Using KRYSTEXXA with Methotrexate
Sep 16, 2020 08:00AM MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Sep 2, 2020 09:00AM Horizon Therapeutics plc Named to the 2020 PEOPLE “50 Companies That Care” List
Sep 1, 2020 08:00AM Horizon Therapeutics plc to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Aug 11, 2020 05:00PM Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
Aug 10, 2020 09:00AM Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crain’s Chicago Business
Aug 7, 2020 06:35AM Horizon Therapeutics (HZNP) Prices 11.8M Share Offering at $71
Aug 6, 2020 11:20PM Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares
Aug 6, 2020 09:00AM Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune
Aug 5, 2020 04:13PM Horizon Therapeutics (HZNP) Announces Proposed $700M Public Offering of Ordinary Shares
Aug 5, 2020 04:01PM Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares
Aug 5, 2020 07:00AM Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EB

HZNP and HPR Related Press Releases

Go Back

Aug 4, 2021 07:00AM Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
Jul 16, 2021 08:30AM Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™
Jul 8, 2021 08:00AM Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021
Jul 1, 2021 11:43AM NIRI Chicago Elects 2021-2022 Officers and Directors
Jun 30, 2021 08:00AM Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021
Jun 29, 2021 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Jun 28, 2021 09:00AM Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 18, 2021 12:30PM Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)
Jun 17, 2021 07:00AM Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics
Jun 2, 2021 08:00AM Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology
May 27, 2021 08:00AM Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
May 24, 2021 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
May 21, 2021 08:00AM Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology
May 20, 2021 08:30AM Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work®
May 13, 2021 11:30AM Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company
May 6, 2021 04:30PM Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference
May 6, 2021 08:30AM New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
May 6, 2021 08:00AM Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen’s Association 2021 Luminary
May 5, 2021 07:00AM Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc
Apr 27, 2021 08:00AM Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide
Apr 21, 2021 07:30AM HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout
Apr 20, 2021 04:04AM Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)
Apr 16, 2021 08:30AM New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 16, 2021 08:00AM New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
Apr 12, 2021 08:30AM Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
Apr 8, 2021 08:00AM Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
Apr 7, 2021 08:00AM RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil
Apr 5, 2021 08:30AM New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology’s 73rd Annual Meeting
Mar 30, 2021 07:30AM Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April
Mar 29, 2021 10:05AM Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership
Mar 25, 2021 08:00AM First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout
Mar 24, 2021 08:15AM UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mar 24, 2021 08:00AM Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community
Mar 15, 2021 08:50AM Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.
Mar 12, 2021 08:45AM Horizon Therapeutics plc Named Number One Best Workplace in Biopharma
Mar 11, 2021 03:00AM Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
Feb 26, 2021 04:05PM Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference
Feb 25, 2021 04:05PM Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish®
Feb 24, 2021 07:00AM Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance
Feb 22, 2021 09:30AM New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase
Feb 4, 2021 01:00AM Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
Feb 3, 2021 08:00AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021
Feb 1, 2021 07:00AM Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
Jan 11, 2021 07:00AM Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New K
Dec 22, 2020 08:00AM Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 17, 2020 06:40AM Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production
Dec 3, 2020 09:00AM Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education
Dec 2, 2020 09:15AM Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
Nov 30, 2020 08:00AM Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities
Nov 25, 2020 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 23, 2020 08:00AM Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 23, 2020 08:00AM Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 17, 2020 09:15AM National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation
Nov 16, 2020 08:00AM First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease
Nov 13, 2020 08:30AM New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration
Nov 13, 2020 08:00AM Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala
Nov 12, 2020 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 2, 2020 02:00PM Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Nov 2, 2020 07:00AM Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITD
Nov 2, 2020 06:58AM Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
Oct 30, 2020 09:15AM Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
Oct 30, 2020 08:00AM New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting
Oct 29, 2020 03:00PM AGC Biologics and Horizon Therapeutics plc Expand Partnership
Oct 29, 2020 08:00AM Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
Oct 26, 2020 08:00AM Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
Oct 23, 2020 08:00AM Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Oct 22, 2020 10:00AM New Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout
Oct 20, 2020 08:00AM Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award
Oct 16, 2020 08:30AM FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year
Oct 14, 2020 08:00AM TEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)
Oct 8, 2020 08:15AM New Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020
Oct 8, 2020 08:00AM Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020
Oct 7, 2020 08:00AM Horizon Therapeutics plc Named One of San Francisco Bay Area’s Best and Brightest Companies to Work For
Oct 5, 2020 08:00AM Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award
Oct 1, 2020 04:00PM Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption
Sep 16, 2020 08:00AM MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Sep 2, 2020 09:00AM Horizon Therapeutics plc Named to the 2020 PEOPLE “50 Companies That Care” List
Sep 1, 2020 08:00AM Horizon Therapeutics plc to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Aug 11, 2020 05:00PM Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
Aug 10, 2020 09:00AM Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crain’s Chicago Business
Aug 6, 2020 11:20PM Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares
Aug 6, 2020 09:00AM Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune
Aug 5, 2020 04:01PM Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares
Aug 5, 2020 07:00AM Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EB

HZNP and HPR Related SEC Filings

Go Back

Aug 4, 2021 07:23AM Form 10-Q Horizon Therapeutics For: Jun 30
Aug 4, 2021 07:13AM Form 8-K Horizon Therapeutics For: Aug 04
Jul 30, 2021 04:30PM Form 4 Horizon Therapeutics For: Jul 28 Filed by: Walbert Timothy P
Jul 30, 2021 04:28PM Form 4 Horizon Therapeutics For: Jul 28 Filed by: SHERMAN JEFFREY W
Jul 30, 2021 04:27PM Form 4 Horizon Therapeutics For: Jul 28 Filed by: Pasternak Andy
Jul 30, 2021 04:27PM Form 4 Horizon Therapeutics For: Jul 28 Filed by: MOZE BARRY
Jul 30, 2021 04:25PM Form 4 Horizon Therapeutics For: Jul 28 Filed by: DesJardin Michael A.
Jul 30, 2021 04:25PM Form 4 Horizon Therapeutics For: Jul 28 Filed by: Hoelscher Paul W.
Jul 30, 2021 04:23PM Form 4 Horizon Therapeutics For: Jul 28 Filed by: Beeler Brian K
Jul 23, 2021 05:01PM Form 4 Horizon Therapeutics For: Jul 22 Filed by: GREY MICHAEL G
Jul 9, 2021 05:01PM Form 4 Horizon Therapeutics For: Jul 08 Filed by: MOZE BARRY
Jul 2, 2021 05:03PM Form 4 Horizon Therapeutics For: Jul 01 Filed by: SHERMAN JEFFREY W
Jul 2, 2021 05:02PM Form 4 Horizon Therapeutics For: Jun 30 Filed by: Walbert Timothy P
Jul 2, 2021 05:02PM Form 4 Horizon Therapeutics For: Jul 01 Filed by: Thompson Elizabeth H.Z.
Jun 22, 2021 01:33PM Form CT ORDER Horizon Therapeutics
Jun 11, 2021 05:00PM Form 4 Horizon Therapeutics For: Jun 10 Filed by: McHugh Miles W
Jun 3, 2021 04:42PM Form 4 Horizon Therapeutics For: Jun 01 Filed by: Walbert Timothy P
May 14, 2021 06:12PM Form 4 Horizon Therapeutics For: May 14 Filed by: Hoelscher Paul W.
May 12, 2021 05:02PM Form 4 Horizon Therapeutics For: May 11 Filed by: Kent Jeff
May 12, 2021 05:01PM Form 4 Horizon Therapeutics For: May 10 Filed by: Daniel William F
May 10, 2021 05:00PM Form 3 Horizon Therapeutics For: Apr 29 Filed by: Thompson Elizabeth H.Z.
May 5, 2021 07:22AM Form 10-Q Horizon Therapeutics For: Mar 31
May 5, 2021 07:10AM Form 8-K Horizon Therapeutics For: May 05
Apr 30, 2021 07:04PM Form 4 Horizon Therapeutics For: Apr 30 Filed by: Walbert Timothy P
Apr 30, 2021 07:03PM Form 4 Horizon Therapeutics For: Apr 29 Filed by: Mahony Susan
Apr 30, 2021 07:02PM Form 4 Horizon Therapeutics For: Apr 29 Filed by: Watkins Thomas
Apr 30, 2021 07:02PM Form 4 Horizon Therapeutics For: Apr 29 Filed by: Witz Pascale
Apr 30, 2021 07:01PM Form 4 Horizon Therapeutics For: Apr 29 Filed by: Shannon James Samuel
Apr 30, 2021 07:00PM Form 4 Horizon Therapeutics For: Apr 29 Filed by: SANTINI GINO
Apr 30, 2021 06:59PM Form 4 Horizon Therapeutics For: Apr 29 Filed by: Himawan Jeff
Apr 30, 2021 06:58PM Form 4 Horizon Therapeutics For: Apr 29 Filed by: GREY MICHAEL G
Apr 30, 2021 06:57PM Form 4 Horizon Therapeutics For: Apr 29 Filed by: Daniel William F
Apr 30, 2021 04:42PM Form S-8 Horizon Therapeutics
Apr 30, 2021 04:41PM Form S-8 Horizon Therapeutics
Apr 30, 2021 04:02PM Form 8-K Horizon Therapeutics For: Apr 29
Apr 13, 2021 06:04PM Form 4 Horizon Therapeutics For: Apr 12 Filed by: MOZE BARRY
Apr 13, 2021 06:03PM Form 4 Horizon Therapeutics For: Apr 12 Filed by: GREY MICHAEL G
Apr 5, 2021 05:26PM Form 4 Horizon Therapeutics For: Apr 05 Filed by: Camardo Daniel A.
Apr 2, 2021 05:14PM Form 4 Horizon Therapeutics For: Apr 01 Filed by: CURTIS GEOFFREY M.
Apr 2, 2021 05:11PM Form 4 Horizon Therapeutics For: Mar 31 Filed by: Beeler Brian K
Mar 31, 2021 05:12PM Form 4 Horizon Therapeutics For: Mar 30 Filed by: Camardo Daniel A.
Mar 30, 2021 07:36AM Form 8-K Horizon Therapeutics For: Mar 30
Mar 17, 2021 05:21PM Form DEFA14A Horizon Therapeutics
Mar 17, 2021 05:19PM Form DEF 14A Horizon Therapeutics For: Apr 29
Mar 15, 2021 09:07AM Form 8-K Horizon Therapeutics For: Mar 15
Mar 5, 2021 04:53PM Form PRE 14A Horizon Therapeutics For: Apr 29
Mar 3, 2021 04:46PM Form 4 Horizon Therapeutics For: Mar 01 Filed by: SANTINI GINO
Mar 3, 2021 04:46PM Form 4 Horizon Therapeutics For: Mar 01 Filed by: Shannon James Samuel
Mar 3, 2021 04:45PM Form 4 Horizon Therapeutics For: Mar 01 Filed by: Walbert Timothy P
Feb 19, 2021 05:02PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: Karnani Vikram
Feb 19, 2021 05:02PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: Kent Jeff
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: CURTIS GEOFFREY M.
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: DesJardin Michael A.
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: Walbert Timothy P
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: Beeler Brian K
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: Hoelscher Paul W.
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: Pasternak Andy
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: SHERMAN JEFFREY W
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: MOZE BARRY
Feb 19, 2021 05:01PM Form 4 Horizon Therapeutics For: Feb 17 Filed by: Konstantinovsky Irina
Feb 12, 2021 05:02PM Form 4 Horizon Therapeutics For: Feb 11 Filed by: DesJardin Michael A.
Feb 11, 2021 06:02AM Form SC 13G/A Horizon Therapeutics Filed by: RENAISSANCE TECHNOLOGIES LLC
Feb 10, 2021 11:03AM Form SC 13G/A Horizon Therapeutics Filed by: VANGUARD GROUP INC
Feb 8, 2021 10:24AM Form SC 13G Horizon Therapeutics Filed by: FMR LLC
Feb 4, 2021 05:40PM Form 4 Horizon Therapeutics For: Feb 02 Filed by: DesJardin Michael A.
Feb 3, 2021 05:25PM Form 4 Horizon Therapeutics For: Feb 01 Filed by: Walbert Timothy P
Feb 1, 2021 07:17AM Form 8-K Horizon Therapeutics For: Jan 31
Jan 29, 2021 09:56AM Form SC 13G/A Horizon Therapeutics Filed by: BlackRock Inc.
Jan 22, 2021 09:10PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: Camardo Daniel A.
Jan 22, 2021 09:09PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: McHugh Miles W
Jan 22, 2021 09:08PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: Beeler Brian K
Jan 22, 2021 09:07PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: CURTIS GEOFFREY M.
Jan 22, 2021 09:06PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: Karnani Vikram
Jan 22, 2021 09:06PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: DesJardin Michael A.
Jan 22, 2021 09:05PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: Konstantinovsky Irina
Jan 22, 2021 09:03PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: Kent Jeff
Jan 22, 2021 09:03PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: MOZE BARRY
Jan 22, 2021 09:02PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: Hoelscher Paul W.
Jan 22, 2021 09:01PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: SHERMAN JEFFREY W
Jan 22, 2021 09:00PM Form 4 Horizon Therapeutics For: Jan 21 Filed by: Walbert Timothy P
Jan 15, 2021 05:44PM Form 4 Horizon Therapeutics For: Jan 15 Filed by: Walbert Timothy P
Jan 11, 2021 07:19AM Form 8-K Horizon Therapeutics For: Jan 11
Jan 8, 2021 05:33PM Form 4 Horizon Therapeutics For: Jan 06 Filed by: Konstantinovsky Irina
Jan 8, 2021 05:32PM Form 4 Horizon Therapeutics For: Jan 06 Filed by: Karnani Vikram
Jan 8, 2021 05:32PM Form 4 Horizon Therapeutics For: Jan 06 Filed by: DesJardin Michael A.
Jan 6, 2021 09:15PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Pasternak Andy
Jan 6, 2021 09:15PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Rosen Karin
Jan 6, 2021 09:14PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Konstantinovsky Irina
Jan 6, 2021 09:13PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: DesJardin Michael A.
Jan 6, 2021 09:12PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Camardo Daniel A.
Jan 6, 2021 09:11PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: McHugh Miles W
Jan 6, 2021 09:11PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: CURTIS GEOFFREY M.
Jan 6, 2021 09:10PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Karnani Vikram
Jan 6, 2021 09:08PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Beeler Brian K
Jan 6, 2021 09:08PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: MOZE BARRY
Jan 6, 2021 09:06PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Kent Jeff
Jan 6, 2021 09:05PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: SHERMAN JEFFREY W
Jan 6, 2021 09:05PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Hoelscher Paul W.
Jan 6, 2021 09:04PM Form 4 Horizon Therapeutics For: Jan 04 Filed by: Walbert Timothy P
Dec 23, 2020 06:03AM Form 8-K Horizon Therapeutics For: Dec 22
Dec 17, 2020 06:06AM Form 8-K Horizon Therapeutics For: Dec 17
Dec 15, 2020 05:01PM Form 4 Horizon Therapeutics For: Dec 14 Filed by: McHugh Miles W
Dec 11, 2020 04:41PM Form 4 Horizon Therapeutics For: Dec 10 Filed by: DesJardin Michael A.
Dec 9, 2020 05:05PM Form 4 Horizon Therapeutics For: Dec 07 Filed by: SHERMAN JEFFREY W
Dec 8, 2020 05:01PM Form 4 Horizon Therapeutics For: Dec 05 Filed by: DesJardin Michael A.
Nov 13, 2020 07:27PM Form 4 Horizon Therapeutics For: Nov 12 Filed by: McHugh Miles W
Nov 6, 2020 06:00PM Form 4 Horizon Therapeutics For: Nov 06 Filed by: Camardo Daniel A.
Nov 6, 2020 06:00PM Form 4 Horizon Therapeutics For: Nov 05 Filed by: Kent Jeff
Nov 6, 2020 06:00PM Form 4 Horizon Therapeutics For: Nov 05 Filed by: MOZE BARRY
Nov 3, 2020 04:25PM Form 4 Horizon Therapeutics For: Nov 01 Filed by: Pasternak Andy
Nov 3, 2020 04:24PM Form 4 Horizon Therapeutics For: Nov 01 Filed by: Rosen Karin
Nov 3, 2020 04:23PM Form 3 Horizon Therapeutics For: Nov 01 Filed by: Rosen Karin
Nov 2, 2020 07:33AM Form 10-Q Horizon Therapeutics For: Sep 30
Nov 2, 2020 07:08AM Form 8-K Horizon Therapeutics For: Nov 02
Oct 22, 2020 06:14PM Form 4/A Horizon Therapeutics For: Oct 21 Filed by: SHERMAN JEFFREY W
Oct 22, 2020 06:14PM Form 4 Horizon Therapeutics For: Oct 01 Filed by: Camardo Daniel A.
Oct 21, 2020 05:07PM Form 4 Horizon Therapeutics For: Oct 21 Filed by: SHERMAN JEFFREY W
Sep 18, 2020 05:00PM Form 4 Horizon Therapeutics For: Sep 16 Filed by: Konstantinovsky Irina
Sep 15, 2020 04:57PM Form 4 Horizon Therapeutics For: Sep 11 Filed by: Konstantinovsky Irina
Sep 8, 2020 04:52PM Form 4 Horizon Therapeutics For: Sep 04 Filed by: Beeler Brian K
Aug 25, 2020 05:16PM Form 4 Horizon Therapeutics For: Aug 24 Filed by: Hoelscher Paul W.
Aug 10, 2020 06:05AM Form 8-K Horizon Therapeutics For: Aug 06
Aug 10, 2020 06:02AM Form 424B5 Horizon Therapeutics
Aug 7, 2020 05:43PM Form 4 Horizon Therapeutics For: Aug 06 Filed by: Walbert Timothy P
Aug 7, 2020 05:41PM Form 4 Horizon Therapeutics For: Aug 05 Filed by: GREY MICHAEL G
Aug 5, 2020 04:03PM Form 424B5 Horizon Therapeutics
Aug 5, 2020 01:27PM Form 4 Horizon Therapeutics For: Aug 03 Filed by: Camardo Daniel A.
Aug 5, 2020 01:26PM Form 3 Horizon Therapeutics For: Jul 30 Filed by: Camardo Daniel A.
Aug 5, 2020 01:25PM Form 4 Horizon Therapeutics For: Aug 03 Filed by: Karnani Vikram
Aug 5, 2020 07:24AM Form 10-Q Horizon Therapeutics For: Jun 30
Aug 5, 2020 07:08AM Form 8-K Horizon Therapeutics For: Aug 03